5 results about "Mucosal inflammation" patented technology

The present invention relates to the field of probiotics, in particular to an Akkermansia muciniphila MG784 for alleviating constipation, promoting defecation, improving intestinal barrier function and intestinal immunity, and its uses. The Akkermansia muciniphila MG784 provided by the present invention has the deposition number DSM 35549. The Akkermansia muciniphila MG784 provided by the present invention can increase the levels of motilin (MTL), gastrin (GAS), and acetylcholine in the gastrointestinal tract, promote intestinal peristalsis, improve the small intestine propulsion rate, and ameliorate defecation time and fecal output. Furthermore, Akkermansia muciniphila MG784 can also alleviate colonic mucosal inflammation, improve the thickness of the digestive tract muscular layer, modulate the structure of the intestinal microbiota, significantly increase the abundance of beneficial bacteria, and decrease the abundance of harmful bacteria.

The present application belongs to the field of biological medicine and food technology, and particularly relates to application of milk-derived extracellular vesicles in improving brain health and / or improving nerve-related discomfort conditions. Compared with the prior art, the present application constructs a chronic restraint stress (CRS) induced anxiety model in adolescent mice, and uses open field test, buried bead test, tail suspension test and other behavioral experiments for functional evaluation. The results show that the milk-derived extracellular vesicles significantly improve the anxiety-like behavior of mice, indicating that the milk-derived extracellular vesicles can significantly improve the anxiety-like behavior of adolescent mice induced by chronic restraint stress (CRS) by remodeling the gut-brain axis function, and that the supplementation of milk-derived extracellular vesicles in adolescents can significantly reduce the susceptibility to anxiety in adulthood. At the same time, the present application also constructs a D-gal induced cognitive impairment model in mice, and the results show that it can reduce the production of pro-inflammatory cytokines, inhibit mucosal inflammation, thereby maintaining intestinal homeostasis and alleviating cognitive impairment.

The invention discloses lactobacillus helveticus PP0208 and application thereof in prevention and treatment of allergic rhinitis, and belongs to the technical field of microorganisms. The technical problem to be solved is to provide the lactobacillus helveticus for treating the allergic rhinitis, and the key point of the technical scheme is that the lactobacillus helveticus PP0208 is provided, and the preservation number of the lactobacillus helveticus PP0208 is CGMCC (China General Microbiological Culture Collection Center) No.28753. The lactobacillus helveticus PP0208 viable bacteria, the thermally inactivated bacteria and the extracellular vesicles of the lactobacillus helveticus PP0208 disclosed by the invention all have the effect of remarkably inhibiting allergic rhinitis mucosal inflammation, can down-regulate the expression of inflammatory factors and regulate the proportion of Treg cells, and cooperatively promotes the development of diseases towards the healing direction by coordinating the intestinal flora structure and the change of metabolites of the intestinal flora structure. The compound has a wide application prospect in preparation of drugs for effectively preventing and treating allergic rhinitis.

A topical cream or ointment is provided that provides for the binding to CB1 and / or CB2 receptors for the soothing of pain, inflammation of smooth muscle, tendons, ligaments, skeletal muscle, endothelial cell, synovial cell, peripheral nerve fibers, reduction of endothelial bruising, promotion of healing of endothelial bruising, and dermatological itch sensation wherein the improvement comprises providing the effect of cannabinoid using plant extracts. A topically administered formulation is also provided for treating anal mucosal inflammation, soothing of pain, inflammation of anal mucosal inflammation; reducing keratinocyte apoptosis; treating viral-associated epithelial damage, treating radiation dermatitis; and treating chemotherapy-induced dermatitis.

The present disclosure relates to 1,4:3,6-dianhydrohexitol, specifically isosorbide, and compositions comprising 1,4:3,6-dianhydrohexitol for treating oral inflammatory conditions. These conditions, which include both oral mucosal inflammation and periodontal diseases, are characterized by elevated levels of pro-inflammatory mediators, particularly IL-1 alpha and IL-8. Using the EpiOral™ model, isosorbide has demonstrated significant ability to reduce IL-1 alpha secretion and IL-8 gene expression in inflamed oral epithelial cells. These results support its therapeutic relevance in treating oral inflammatory conditions through modulation of key inflammatory mediators.